AU2002327049B2 - Development of a preventive vaccine for filovirus infection in primates - Google Patents

Development of a preventive vaccine for filovirus infection in primates Download PDF

Info

Publication number
AU2002327049B2
AU2002327049B2 AU2002327049A AU2002327049A AU2002327049B2 AU 2002327049 B2 AU2002327049 B2 AU 2002327049B2 AU 2002327049 A AU2002327049 A AU 2002327049A AU 2002327049 A AU2002327049 A AU 2002327049A AU 2002327049 B2 AU2002327049 B2 AU 2002327049B2
Authority
AU
Australia
Prior art keywords
replication
domain
composition
virus
genetic construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002327049A
Other languages
English (en)
Other versions
AU2002327049A1 (en
Inventor
Gary J. Nabel
Anthony Sanchez
Nancy Sullivan
Zhi-Yong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government Of United States, As Represented By Secretary
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of United States, As Represented By Secretary, Government of the United States of America filed Critical Government Of United States, As Represented By Secretary
Publication of AU2002327049A1 publication Critical patent/AU2002327049A1/en
Priority to AU2005244541A priority Critical patent/AU2005244541B2/en
Application granted granted Critical
Publication of AU2002327049B2 publication Critical patent/AU2002327049B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2002327049A 2001-10-01 2002-09-24 Development of a preventive vaccine for filovirus infection in primates Expired AU2002327049B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005244541A AU2005244541B2 (en) 2001-10-01 2005-12-15 Development of a preventative vaccine for filovirus infection in primates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32647601P 2001-10-01 2001-10-01
US60/326,476 2001-10-01
PCT/US2002/030251 WO2003028632A2 (en) 2001-10-01 2002-09-24 Development of a preventive vaccine for filovirus infection in primates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005244541A Division AU2005244541B2 (en) 2001-10-01 2005-12-15 Development of a preventative vaccine for filovirus infection in primates

Publications (2)

Publication Number Publication Date
AU2002327049A1 AU2002327049A1 (en) 2003-06-26
AU2002327049B2 true AU2002327049B2 (en) 2008-04-03

Family

ID=23272371

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002327049A Expired AU2002327049B2 (en) 2001-10-01 2002-09-24 Development of a preventive vaccine for filovirus infection in primates

Country Status (9)

Country Link
US (5) US7635688B2 (https=)
EP (1) EP1504112A4 (https=)
JP (2) JP2005508916A (https=)
AT (1) ATE396739T1 (https=)
AU (1) AU2002327049B2 (https=)
CA (4) CA2776391C (https=)
DE (1) DE60226911D1 (https=)
ES (1) ES2307093T3 (https=)
WO (1) WO2003028632A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012538A2 (en) 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Accelerated vaccination
ES2388527T3 (es) 2003-09-15 2012-10-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vacunas de VIH basadas en Env de múltiples clados de VIH
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
AU2005243730B2 (en) * 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
JP4772045B2 (ja) * 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
AU2005289439B2 (en) 2004-09-27 2011-12-01 Crucell Holland B.V. Optimized vaccines to provide protection against Ebola and other viruses
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
SG169996A1 (en) * 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
WO2009092038A1 (en) * 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
BRPI0914847A2 (pt) 2008-06-20 2020-12-15 Basf Se Formulação agroquímica, processo para a preparação da composição, kit de partes, usos de uma mistura de um filtro fotoprotetor orgânico, e da formulação agroquímica, e, métodos para combater insetos prejudiciais e/ou de fungos fitopatogênicos, e para controlar vegetação indesejada
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
CA2744817C (en) 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2010062396A2 (en) 2008-11-26 2010-06-03 Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US9125411B2 (en) 2010-04-15 2015-09-08 Basf Se UV absorbers for reducing the E/Z isomerization of pesticides
EP2560680B1 (en) 2010-04-16 2018-11-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Chimpanzee adenoviral vector-based filovirus vaccines
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
DK2655604T3 (en) * 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
WO2012170814A1 (en) * 2011-06-08 2012-12-13 The Ohio State University Norovirus immunogens and related materials and methods
EP3662935A1 (en) * 2011-07-11 2020-06-10 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA3194125A1 (en) * 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US10744199B2 (en) 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
TWI516602B (zh) 2013-10-29 2016-01-11 臺北醫學大學 高通量篩選高表現細胞之方法及由其篩選之細胞
CA2950085A1 (en) 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
SG11201705782QA (en) * 2015-01-28 2017-08-30 Integrated Biotherapeutics Inc Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases
KR20180088458A (ko) 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
SG11201901790YA (en) 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
CN111163801A (zh) 2017-08-02 2020-05-15 美国卫生与公众服务部 用于流感病毒的基于乙型肝炎纳米颗粒的疫苗
US20210220463A1 (en) * 2018-05-18 2021-07-22 UNIVERSITé LAVAL Vectors for dna vaccination
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
WO2024138204A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized pfs48/45 proteins and uses thereof
WO2025184403A2 (en) * 2024-02-29 2025-09-04 Memorial Sloan-Kettering Cancer Center Cell penetrating peptides and methods including the same
CN121494944A (zh) * 2026-01-13 2026-02-10 中国人民解放军军事科学院军事医学研究院 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171596B1 (en) 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6200959B1 (en) 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6630144B1 (en) 1999-08-30 2003-10-07 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies to Ebola glycoprotein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sullivan et al. Development of a preventative vaccine for Ebola virus infection in primates. Nature November 2000 vol. 408 pages 605-609. *

Also Published As

Publication number Publication date
US7635688B2 (en) 2009-12-22
JP2005508916A (ja) 2005-04-07
CA2462455A1 (en) 2003-04-10
US8106026B2 (en) 2012-01-31
WO2003028632A3 (en) 2004-12-02
CA2776391A1 (en) 2003-04-10
DE60226911D1 (de) 2008-07-10
US8124592B2 (en) 2012-02-28
CA2776522A1 (en) 2003-04-10
ATE396739T1 (de) 2008-06-15
JP4198148B2 (ja) 2008-12-17
CA2776272C (en) 2016-05-17
US20100298414A1 (en) 2010-11-25
WO2003028632A2 (en) 2003-04-10
US20040259825A1 (en) 2004-12-23
CA2776272A1 (en) 2003-04-10
US8106027B2 (en) 2012-01-31
US20060148087A1 (en) 2006-07-06
US20100303857A1 (en) 2010-12-02
CA2776391C (en) 2015-03-31
CA2462455C (en) 2012-07-17
EP1504112A2 (en) 2005-02-09
CA2776522C (en) 2015-02-17
EP1504112A4 (en) 2006-02-08
JP2006081549A (ja) 2006-03-30
US20100297171A1 (en) 2010-11-25
US7094598B2 (en) 2006-08-22
ES2307093T3 (es) 2008-11-16

Similar Documents

Publication Publication Date Title
AU2002327049B2 (en) Development of a preventive vaccine for filovirus infection in primates
WO2003028632A9 (en) Development of a preventive vaccine for filovirus infection in primates
AU2002327049A1 (en) Development of a preventive vaccine for filovirus infection in primates
US11913013B2 (en) Chimpanzee adenoviral vector-based filovirus vaccines
US9012618B2 (en) Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures
WO2007100584A2 (en) Antiviral agents and vaccines against influenza
EP1586331B1 (en) Development of a preventive vaccine for filovirus infection in primates
AU2005244541B2 (en) Development of a preventative vaccine for filovirus infection in primates
CA2519282C (en) Development of a preventive vaccine for filovirus infection in primates

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
TH Corrigenda

Free format text: IN VOL 22, NO 26, PAGE(S) 3068 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED 2002 DELETE ALL REFERENCE TO 2002327049.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired